First Dallas Securities Inc. Has $561,000 Stock Position in Pfizer Inc. (NYSE:PFE)

First Dallas Securities Inc. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 36.0% in the 1st quarter, HoldingsChannel reports. The firm owned 20,200 shares of the biopharmaceutical company’s stock after acquiring an additional 5,350 shares during the period. First Dallas Securities Inc.’s holdings in Pfizer were worth $561,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in PFE. VisionPoint Advisory Group LLC lifted its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC lifted its holdings in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the period. Creekmur Asset Management LLC bought a new stake in Pfizer during the fourth quarter worth $32,000. Tennessee Valley Asset Management Partners bought a new stake in Pfizer during the fourth quarter worth $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new stake in Pfizer during the fourth quarter worth $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock traded up $0.18 during mid-day trading on Friday, hitting $27.98. 33,189,215 shares of the stock were exchanged, compared to its average volume of 34,031,364. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80. The stock has a market capitalization of $158.55 billion, a price-to-earnings ratio of -466.42, a PEG ratio of 1.09 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The business has a fifty day moving average price of $27.90 and a 200 day moving average price of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the previous year, the business earned $1.23 EPS. Pfizer’s revenue was down 19.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday. Ten equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.